高系统性免疫炎症指数（SIII）在各种癌症（包括胰腺癌）诊断时与不良预后相关。FOLFIRINOX（5-氟脲嘧啶、亚叶酸钙、伊立替康和奥沙利铂）化疗或立体定向放射治疗（SBRT）对该指数的影响尚不清楚。此外，在治疗期间SIII变化的预后价值也不清楚。在这项回顾性分析中，我们旨在找到针对晚期胰腺癌患者的答案。 包括2015年至2021年间在两个三级转诊中心接受FOLFIRINOX化疗或FOLFIRINOX化疗后接受SBRT治疗的晚期胰腺癌患者。收集基线特征、治疗过程中的三个时间点的实验室指标和生存结果。使用联合模型对纵向和时间-事件数据评估患者特定的SIII演变及其与死亡率的关联。 分析了141名患者的数据。在中位随访时间23.0个月（95％CI 14.6-31.3）后，97（69％）名患者已经去世。中位总生存期（OS）为13.2个月（95％CI 11.0-15.5）。在接受FOLFIRINOX治疗期间，log（SIII）降低了-0.588（95％CI -0.0978，-0.197；P = 0.003）。log（SIII）每增加1个单位，死亡的风险比增加1.604（95％CI 1.068-2.409；P = 0.023）。 除了CA19-9外，SIII是晚期胰腺癌患者的可靠生物标志物。©2023年作者（们）版权所有。 Wolters Kluwer Health, Inc. 发布。

A high Systemic Immune-Inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) chemotherapy or stereotactic body radiation (SBRT) on this index is unknown. In addition, the prognostic value of changes in the SIII during treatment is unclear. In this retrospective analysis, we aimed to find answers regarding patients with advanced pancreatic cancer.Patients with advanced pancreatic cancer treated with FOLFIRINOX chemotherapy alone or with FOLFIRINOX chemotherapy followed by SBRT between 2015 and 2021 in two tertiary referral centers were included. Baseline characteristics, laboratory values at three time points during treatment and survival outcomes were collected. The subject-specific evolutions of SIII and their association with mortality were assessed with joint models for longitudinal and time-to-event data.Data of 141 patients were analyzed. At a median follow up time of 23.0 months (95%CI 14.6 - 31.3), 97 (69%) patients had died. Median overall survival (OS) was 13.2 months (95%CI 11.0 - 15.5). During treatment with FOLFIRINOX the log(SIII) was reduced by -0.588 (95%CI -0.0978, -0.197; P=0.003). One unit increase in log(SIII) increased the hazard ratio of dying by 1.604 (95%CI 1.068 - 2.409; P=0.023).In addition to CA 19-9, the SIII is a reliable biomarker in patients with advanced pancreatic cancer.Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.